Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications.

about

Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications.

Item

http://www.wikidata.org/entity/Q38804715

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cardiac safety of systemic the ...... atherosclerosis complications.

@en

type

Item

label

Cardiac safety of systemic the ...... atherosclerosis complications.

@en

prefLabel

Cardiac safety of systemic the ...... atherosclerosis complications.

@en

P1476

Cardiac safety of systemic the ...... atherosclerosis complications

@en

P2093

Arthur Matyszewski

http://www.w3.org/2001/XMLSchema#string

Cezary Szczylik

http://www.w3.org/2001/XMLSchema#string

Jarosław D Kasprzak

http://www.w3.org/2001/XMLSchema#string

Marta Nowakowska

http://www.w3.org/2001/XMLSchema#string

Zdzisława Kornacewicz-Jach

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

Cardiac dysfunction in the trastuzumab clinical trials experience

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

A clinicopathologic analysis of adriamycin cardiotoxicity.

Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study

P304

593-602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0425

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anna M Czarnecka

Paweł Stachowiak

P577

2016-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27784174

http://www.w3.org/2001/XMLSchema#string